

Fig. 1




Fig. 2

· . . .




Fig. 3 ...

.....





Fig. 4

Anti-E1 levels in NON-responders to IFN treatment




weeks after start of treatment Fig. 5


≥ ¥ I B 0 80 . 70 Anti-E1 levels in RESPONDERS to IFN treatment 9 weeks after start of treatment 20 40 SERIES 1 30 20 20 Z Z S/N 910 ω 0 9 4 2 12

Fig. 6

Anti-E1 levels in patients with COMPLETE response to IFN



Anti-E1 levels in INCOMPLETE responders to IFN treatment




months after start of treatment Fig. 8

N 30 * 15 **₩** Anti-E2 levels in NON-RESPONDERS to IFN treatment 92 02 99 9 55 20 20 25 30 35 40 45 SERIES 1 5 10 15 N N လ် Z/S ω 9 2 0 2

weeks after start of treatment Fig. 9


ql ₩ al H ◆ 0 3a p lb 70 75 80 Anti-E2 levels in RESPONDERS to IFN treatment 90 92 55 20 weeks after start of treatment 10 15 20 25 30 35 40 45 SERIES 1 Fig. 10 N N N/S CI ω 9 0 12 14


Anti-E2 levels in INCOMPLETE responders to IFN treatment



ponins dilei sidii or iledii nei **Fig.11**

Anti-E2 levels in COMPLETE responders to IFN treatment





Competition of reactivity of anti-E1 Mabs with peptides






Fig. 14


Anti-E1 (epitope 1) levels in NON-RESPONDERS to IFN treatment




Anti-E1 (epitope 1) levels in RESPONDERS to IFN treatment



Anti-E1 (epitope 2) levels in NON-RESPONDERS to IFN treatment



Anti-E1 (epitope 2) levels in RESPONDERS to IFN treatment






Fig.19




Fig. 20



Fig. 21A

5' GGCATGCAAGCTTAATTAATT3' (SEQ ID NO 1)
3'ACGTCCGTACGTTCGAATTAATTAATCGA5' (SEQ ID NO 94)

SEQ ID NO 3 (HCC19A)

SEQ ID NO 5 (HCCI10AL



Fig. 21B

SEQ ID NO 7 (HCCI11A)

SEQ ID NO 9 (HCCI12A)

SEQ ID NO 11 (HCCI13A)



Fig. 21C

GCCCTGCGTTCGGGAGGGCAACTCCTCCCGTTGCTGGGTGGCGCTCACTCCCACGCTC
GCGGCCAGGAACGCCAGCGTCCCCACAACGACAATACGACGCCACGTCGATTTGCTC
GTTGGGGCTGCTGCTTCTGTTCCGCTATGTACGTGGGGGATCTCTGCGGATCTGTTT
CCTTGTTTCCCAGCTGTTCACCTTCTCACCTCGCCGGCATCAAACAGTACAGGACTGCA
ACTGCTCAATCTATCCCGGCCATGTATCAGGTCACCGCATGGCTTGGGATATGATGAT
GAACTGGTAATAG

SEQ ID NO 13 (HCCI17A)

SEQ ID NO 15 (HCPr51)
ATGCCCGGTTGCTCTTTCTCTATCTT

SEQ ID NO 16 (HCPr52)
ATGTTGGGTAAGGTCATCGATACCCT

SEQ ID NO 17 (HCPr53)
CTATTAGGACCAGTTCATCATCATATCCCA

SEQ ID NO 18 (HCPr54)
CTATTACCAGTTCATCATCATATCCCA

SEQ ID NO 19 (HCPr107)
ATACGACGCCACGTCGATTCCCAGCTGTTCACCATC



Fig. 21D

SEQ ID NO 20 (HCPr108)
GATGGTGAACAGCTGGGAATCGACGTGGCGTCGTAT

SEQ ID NO 21 (HCCI37)

SEQ ID NO 23 (HCCI38)

SEQ ID NO 25 (HCC139)

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT



Fig. 21E

SEQ ID NO 27 (HCC140)

SEQ ID NO 29 (HCCI62)

ATGGGTAAGGTCATCGATACCCTTACGTGCGGATTCGCCGATCTCATGGGGTACATCC
CGCTCGTCGCGCTCCCGTAGGAGGCGTCGCAAGAGCCCTTGCGCATGGCGTGAGGGC
CCTTGAAGACGGGATAAATTTCGCAACAGGGAATTTGCCCGGTTGCTCCTTTTCTATTT
TCCTTCTCGCTCTGTTCTCTTGCTTAATTCATCCAGCAGCTAGTCTAGAGTGGCGGAAT
ACGTCTGGCCTCTATGTCCTTACCAACGACTGTTCCAATAGCAGTATTGTGTACGAGGC
CGATGACGTTATTCTGCACACCCCGGCTGCATACCTTGTGTCCAGGACGGCAATACA
TCCACGTGCTGGACCCCAGTGACACCTACAGTGGCAGTCAAGTACGTCGGAGCAACCA
CCGCTTCGATACGCAGTCATGTGGACCTATTAGTGGGCGCGGCCACGATGTGCTCTGC
GCTCTACGTGGGTGACATGTGTGGGGCTGTCTTCCTCGTGGGACAAGCCTTCACGTTCA
GACCTCGTCGCCATCAAACGGTCCAGACCTGTAACTGCTCGCTGTACCCAGGCCATCT
TTCAGGACATCGAATGGCTTGGGATATGATGATGAACTGGTAATAG



Fig. 21F

SEQ ID NO 31 (HCCl63)

ATGGGTAAGGTCATCGATACCCTAACGTGCGGATTCGCCGATCTCATGGGGTATATCC
CGCTCGTAGGCGCCCCATTGGGGGCGTCGCAAGGGCTCTCGCACACGGTGTGAGGGT
CCTTGAGGACGGGGTAAACTATGCAACAGGGAATTTACCCGGTTGCTCTTTCTCTATCT
TTATTCTTGCTCTTCTCTCGTGTCTGACCGTTCCGGCCTCTGCAGTTCCCTACCGAAATG
CCTCTGGGATTTATCATGTTACCAATGATTGCCCAAACTCTTCCATAGTCTATGAGGCA
GATAACCTGATCCTACACGCACCTGGTTGCGTGCCTTGTGTCATGACAGGTAATGTGA
GTAGATGCTGGGTCCAAATTACCCCTACACTGTCAGCCCCGAGCCTCGGAGCAGTCAC
GGCTCCTCTTCGGAGAGCCGTTGACTACCTAGCGGGAGGGGCTGCCCTCTGCTCCGCG
TTATACGTAGGAGACGCGTTGGGGCACTATTCTTGGTAGGCCAAATGTTCACCTATA
GGCCTCGCCAGCACGCTACGGTGCAGAACTGCAACTGTTCCATTTACAGTGGCCATGT
TACCGGCCACCGGATGGCATGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 33 (HCPr109) TGGGATATGATGATGAACTGGTC

SEQ ID NO 34 (HCPr72)
CTATTATGGTGGTAAKGCCARCARGAGCAGGAG

SEQ ID NO 35 (HCCL22A)



Fig. 21G

CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT
TAGGATGTACGTGGGGGGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCG
AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG
TCTACAACAGAGTGGCAGATACTGCCCTGTTCCTTCACCACCCTGCCGGCCCTATCCA
CCGGCCTGATCCACCTCCATCAGAACATCGTGGACGTGCAATACCTGTACGGTGTAGG
GTCGGCGGTTGTCTCCCTTGTCATCAAATGGGAGTATGTCCTGTTGCTCTTCCTT
GGCAGACGCGCGCATCTGCGCCTGCTTATGGATGATGCTGATAGCTCAAGCTGAG
GCCGCCTTAGAGAACCTGGTGGTCCTCAATGCGGCGGCCGTGGCCGGGGCGCATGGC
ACTCTTTCCTTCCTTGTGTTCTTCTGTGCTGCCTGGTACATCAAGGGCAGGCTGGTCCC
TGGTGCGGCATACGCCTTCTATGGCGTGGCCGCTGCTCCTGCTTCTGCTGGCCTTAC
CACCACGAGCTTATGCCTAGTAA

SEQ ID NO 37 (HCCI41)

GATCCCACAAGCTGTCGTGGACATGGTGGCGGGGCCCATTGGGGAGTCCTGGCGG CCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCT TTGCCGGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCA GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAATCCAGCTCGTAAACAC AGGGTTCTTTGCCGCACTATTCTACAACACACAATTCAACTCGTCTGGATGCCCAGAG CGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTT ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC **GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC** CTGTTGTGGTGGGGACGACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAA CGACTCGGATGTGCTGATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGC TGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACA CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT TAGGATGTACGTGGGGGGCGTGGAGCCACAGGTTCGAAGCCGCATGCAATTGGACTCG AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG

SEQ ID NO 39 (HCC142)



Fig. 21H

TTGCCGGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCA GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACAC AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG CGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTT ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC CGACTCGGATGTGCTGATTCTCAACACGCGGCGGCCGCCGCGAGGCAACTGGTTCGGC TGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACA CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCG AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTG TCTACAACAGGTGATCGAGGGCAGACACCATCACCACCATCACTAATAG

SEQ ID NO 41 (HCCI43)

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACG GGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCT CTTTAGCCCCGGGTCGGCTCAGAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC TATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCG CTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC GACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTG ATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATG GCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGCCGGCA ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGC CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGG GGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGA CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGG CAGAGCTTAATTAATTAG



Fig. 21I

SEQ ID NO 43 (HCCI44)

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACG GGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCT CTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC TATTCTACAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCG CTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC GACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTG ATFCTCAACACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATG GCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCA ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGC CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGG GGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGA CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGGTGAT CGAGGGCAGACACCATCACCACCATCACTAATAG

SEQ ID NO 45 (HCCL64)



Fig. 21J

SEQ ID NO 47 (HCC165)

AATTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA TTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG GGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT ATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG CAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTAT GAGGCAGCGGACATGATCATGCACACCCCGGGTGCGTGCCCTGCGTTCGGGAGAAC AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG TCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTTTCTG TTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCA CCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGG CCACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACG GCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCGTGGACATGGTGGCGG GGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACTGGGC TAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGTGTCAG GAGGGCAGCAGCCTCCGATACCAGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGC TCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACTGCCCT GAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAACACAAA TTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCG CTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGGCCCTA CTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGT CCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTTTGGTGT CCCCACGTATAACTGGGGGGGGAACGACTCGGATGTGCTGATTCTCAACAACACGCGG CCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCACCAAGA CGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTTGACCTGCC



Fig. 21K

SEQ ID NO 49 (HCC166)

ATGAGCACGAATCCTAAACCTCAAAGAAAAACCAAACGTAACACCAACCGCCGCCCA CAGGACGTCAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGC GCAGGGGCCCCAGGTTGGGTGTGCGCGCGACTAGGAAGACTTCCGAGCGGTCGCAAC CTCGTGGGAGGCGACAACCTATCCCCAAGGCTCGCCGACCCGAGGGTAGGGCCTGGG CTCAGCCCGGGTACCCTTGGCCCCTCTATGGCAATGAGGGCATGGGGTGGGCAGGATG GCTCCTGTCACCCCGCGCCTCCGGCCTAGTTGGGGCCCTACAGACCCCCGGCGTAGG TCGCGTAATTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGG GGTACATTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGG CGTCCGGGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCT TTCTCTATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAA GTGCGCAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTG GAACAACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCC AGCGTCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTT TCTGTTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTG TTCACCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATC CCGGCCACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTAC AACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCGTGGACATGGTG GCGGGGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACT GGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGT GTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGG



Fig. 21L

TCGGCTCAGAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACT GCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAAC ACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAA GTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGG CCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGT GCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTT TGGTGTCCCCACGTATAACTGGGGGGGGGAACGACTCGGATGTGCTGATTCTCAACAAC **ACGCGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCA** CCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACACACCTTGA CCTGCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTC TGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTAC ACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACA GGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATACTGCC CTGTTCCTTCACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAAC ATCGTGGACGTGCAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCATCA AATGGGAGTATGTCCTGTTGCTCTTCCTTCCTGGCAGACGCGCGCATCTGCGCCTGC TTATGGATGATGCTGATAGCTCAAGCTGAGGCCGCCTTAGAGAACCTGGTGGTCC GCTGCCTGGTACATCAAGGGCAGGCTGGTCCCTGGTGCGGCATACGCCTTCTATGGCG TGTGGCCGCTGCTCCTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAA







Fig. 22

OD measured at 450 nm construct

Fraction	volume dilution	39	40	62 .	63	
		Type	Type	Туре	Typ∈	
		Ib	16	3a	5a	
						_
START	23 ml 1/20	2.517	1.954	1.426	1.142	
FLOW THROUGH 23 ml 1/20 1 0.4 ml 1/200 2 3		0.087	0.085	0.176	0.120	
		0.102	0.051	0.048	70.050	
		0.396	0.550	0.090	0.067	
		2.627	2.603	2.481	2.372	
4			2.967	3	2.694	
5		3 3	2.810	2.640	2.154	
6		2.694	2.499	1.359	1.561	
7		2.408	2.481	0.347	1.390	
\$		2.176	1.970	1.624	0.865	
ġ		1.461	1.422	0.887	0.604	
10		1.286	0.926	0.543	0.519	
11		0.981	0.781	0.294	0.294	
12		0.812	0.650	0.249	0.199	
13		0.373	0.432	0.239	0.209	
14 .		0.653	0.371	0.145	0.184	
15		0.441	0.348	. 0.151	0.151	
16		0.321	0.374	0.098	0.106	
17		0.525	0.186	0.099	0.108	
18		0.351	0.171	0.083	0.090	
19		0.192	0.164	0.084	0.087	
17		0.175	*··•			







Fig. 25






Fig.27






Fig.28

M 1 2 3 4 5 6 Fig. 29

67 kD -

45 kD -

29 kD -

18 kD -

14 kD -

Lane 1: Crude Lysate

Lane 2: Flow through Lentil Chromatography

Lane 3: Wash with EMPIGEN Lentil Chromatography

Lane 4: Eluate Lentil Chromatography

Lane 5: Flow through during concentration lentil cluate

Lane 6: Pool of Elafter Size Exclusion Chromatography





Fig. 30










Fig. 31B








- 1. 30 mM IMIDAZOLE WASH Ni-IMAC
- 2. 0.5 ug E2

Fig.33




No.	Ret. (ml)	Peak start (ml)	Peak end (ml)	Dur (ml)	Area (ml*mAU)	Height (mAU)
1	-0.45	-0.46	-0.43	0.04	0.0976	4.579
2	1.55	0.75	3.26	2.51	796.4167	889.377
3	3.27	3.26	3.31	0.05	0.0067	0.224
4	3.33	3.32	3.33	0.02	0.0002	0.018

Total number of detected peaks = 4
Total Area above baseline = 0.796522 ml*AU
Total area in evaluated peaks = 0.796521 ml*AU
Ratio peak area / total area = 0.999999
Total peak duration = 2.613583 ml

Fig. 34










NS4 Ab LTR 200 150 LIA-scan 100 50 Start 12 mo

Fig. 35A-1

Fig. 35A-2










Fig. 35A-5

Fig. 35A-6






Fig. 35A-7




Fig. 35A-8








Fig. 35B-1




Fig. 35B-2




Fig. 35B-3




Fig. 35B-4




Fig. 35B-5




Fig. 35B-6






Fig. 35B-7




Fig. 35B-8

Fig. 36A E1 Ab







Fig. 36B **E2 Ab**







Relative Map Positions of anti-E2 monoclonal antibodies




Fig.39 -106.0nm004 OF HCV E1 ENVELOPE PROTEIN Glycopeptidase f (PNGase F) PARTIAL DEGLYCOSYLATION nm0+ ոաե um4.0 um10.0 ոաօ Endoglycosidase H (Endo H) ոաց uma.0 nш*ៅ*09 n*1*19 u*t*l9.0 n*r*l0 6 5 4 4 4 4 က

PARTIAL TREATMENT OF HCV E2\E2s ENVELOPE PROTEINS BY PNGase F

	кDа - 106	- 80	- 49.5	- 32.5	
E2s (vvHCV-41)	Umî			8 4 4 4	
	Umt.0		11 2		
	Umto.o				
	Uμt		-		
	U4r.0		编载计		
	U410.0		3		
	•		11////	0000	
E2 (vvHCV-64)	Umt		<u>.</u>		
	Umf.0		1.	<u>(</u>	
	Umto.o				
	Uul		(4) (4) (4) (4) (4) (4) (4) (4) (4) (4)		
	U41.0			3	
	U410.0			· ·	
	-	ı	13 42		
	кDа 106 -	80	- 5'6†	32.5	

Fig. 40

Fig. 41 In Vitro Mutagenesis of HCV E1 glycoprotein






Fig. 42A In Vitro Mutagenesis of HCV E1 glycoprotein



1. First step of PCR amplification (Gly-# and Ovr-# primers)







Fig. 43 In Vitro Mutagenesis of HCV E1 glycoprotein






Fig.44A



Fig.44B



Fig. 45

Fig.46